-
1
-
-
61849185913
-
Recent developments in Alzheimer's disease therapeutics
-
Rafii MS, Aisen PS: Recent developments in Alzheimer's disease therapeutics. BMC Med 7: 7, 2009
-
(2009)
BMC Med
, vol.7
, pp. 7
-
-
Rafii, M.S.1
Aisen, P.S.2
-
2
-
-
77951776829
-
Alzheimer's disease: Strategies for disease modification
-
Citron M: Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov 9: 387-398, 2010
-
(2010)
Nat Rev Drug Discov
, vol.9
, pp. 387-398
-
-
Citron, M.1
-
3
-
-
77953778864
-
Treatment of Alzheimer's disease: Symptomatic and disease-modifying approaches
-
Galimberti D, Scarpini E: Treatment of Alzheimer's disease: symptomatic and disease-modifying approaches. Curr Aging Sci 3: 46-56, 2010
-
(2010)
Curr Aging Sci
, vol.3
, pp. 46-56
-
-
Galimberti, D.1
Scarpini, E.2
-
4
-
-
0011162190
-
Selective loss of central cholinergic neurons in Alzheimer's disease
-
Davies P, Maloney AJ: Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2: 1403, 1976 (Pubitemid 8004505)
-
(1976)
Lancet
, vol.2
, Issue.8000
, pp. 1403
-
-
Davies, P.1
Maloney, A.J.F.2
-
5
-
-
0019410162
-
Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis
-
DOI 10.1002/ana.410100203
-
Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR: Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 10: 122-126, 1981 (Pubitemid 11053099)
-
(1981)
Annals of Neurology
, vol.10
, Issue.2
, pp. 122-126
-
-
Whitehouse, P.J.1
Price, D.L.2
Clark, A.W.3
-
6
-
-
0024576043
-
The pontomesecephalotegmental cholinergic system does not degenerate in Alzheimer's disease
-
Woolf NJ, Jacobs RW, Butcher LL: The pontomesecephalotegmental cholinergic system does not degenerate in Alzheimer's disease. Neurosci Lett 96: 277-282, 1989
-
(1989)
Neurosci Lett
, vol.96
, pp. 277-282
-
-
Woolf, N.J.1
Jacobs, R.W.2
Butcher, L.L.3
-
7
-
-
0024315598
-
Nerve growth factor receptor is associated with cholinergic neurons of the basal forebrain but not the pontomesencephalon
-
DOI 10.1016/0306-4522(89)90360-6
-
Woolf NJ, Gould E, Butcher LL: Nerve growth factor receptor is associated with cholinergic neurons of the basal forebrain but not the pontomesencephalon. Neuroscience 30: 143-152, 1989 (Pubitemid 19159803)
-
(1989)
Neuroscience
, vol.30
, Issue.1
, pp. 143-152
-
-
Woolf, N.J.1
Gould, E.2
Butcher, L.L.3
-
8
-
-
0025110182
-
β-Amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage
-
DOI 10.1016/0006-8993(90)91355-K
-
Koh JY, Yang LL, Cotman CW: β-amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage. Brain Res 533: 315-320, 1990 (Pubitemid 20377714)
-
(1990)
Brain Research
, vol.533
, Issue.2
, pp. 315-320
-
-
Koh, J.-Y.1
Yang, L.L.2
Cotman, C.W.3
-
9
-
-
0027973241
-
Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia
-
Mesulam MM, Geula C: Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia. Ann Neurol 36: 722-727, 1994
-
(1994)
Ann Neurol
, vol.36
, pp. 722-727
-
-
Mesulam, M.M.1
Geula, C.2
-
10
-
-
0027337833
-
Neuroglial cholinesterases in the normal brain and in Alzheimer's disease: Relationship to plaques, tangles, and patterns of selective vulnerability
-
Wright CI, Geula C, Mesulam MM: Neurological cholinesterases in the normal brain and in Alzheimer's disease: relationship to plaques, tangles, and patterns of selective vulnerability. Ann Neurol 34: 373-384, 1993 (Pubitemid 23259607)
-
(1993)
Annals of Neurology
, vol.34
, Issue.3
, pp. 373-384
-
-
Wright, C.I.1
Geula, C.2
Mesulam, M.-M.3
-
11
-
-
34547211420
-
Galanthamine, a natural product for the treatment of Alzheimer's disease
-
Marco L, do Carmo Carreiras M: Galanthamine, a natural product for the treatment of Alzheimer's disease. Recent Pat CNS Drug Discov 1: 105-111, 2006
-
(2006)
Recent Pat CNS Drug Discov
, vol.1
, pp. 105-111
-
-
Marco, L.1
Do Carmo Carreiras, M.2
-
12
-
-
0034732104
-
Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease
-
DOI 10.1016/S0014-2999(00)00093-5, PII S0014299900000935
-
Maelicke A, Albuquerque EX: Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease. Eur J Pharmacol 393: 165-170, 2000 (Pubitemid 30193413)
-
(2000)
European Journal of Pharmacology
, vol.393
, Issue.1-3
, pp. 165-170
-
-
Maelicke, A.1
Albuquerque, E.X.2
-
13
-
-
10744232323
-
Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors
-
DOI 10.1124/jpet.102.045773
-
Samochocki M, Hoffle A, Fehrenbacher A, Jostock R, Ludwig J, et al: Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmacol Exp Ther 305: 1024-1036, 2003 (Pubitemid 36617980)
-
(2003)
Journal of Pharmacology and Experimental Therapeutics
, vol.305
, Issue.3
, pp. 1024-1036
-
-
Samochocki, M.1
Hoffle, A.2
Fehrenbacher, A.3
Jostock, R.4
Ludwig, J.5
Christner, C.6
Radina, M.7
Zerlin, M.8
Ullmer, C.9
Pereira, E.F.R.10
Lubbert, H.11
Albuquerque, E.X.12
Maelicke, A.13
-
14
-
-
0035852773
-
Galantamine: Effect on nicotinic receptor binding, acetylcholinesterase inhibition, and learning
-
DOI 10.1073/pnas.031584398
-
Woodruff-Pak DS, Vogel RW, 3rd, Wenk GL: Galantamine: effect on nicotinic receptor binding, acetylcholinesterase inhibition, and learning. Proc Natl Acad Sci U S A 98: 2089-2094, 2001 (Pubitemid 32165627)
-
(2001)
Proceedings of the National Academy of Sciences of the United States of America
, vol.98
, Issue.4
, pp. 2089-2094
-
-
Woodruff-Pak, D.S.1
Vogel III, R.W.2
Wenk, G.L.3
-
15
-
-
78650057569
-
Galantamine-induced amyloid- {β} clearance mediated via stimulation of microglial nicotinic acetylcholine receptors
-
Takata K, Kitamura Y, Saeki M, Terada M, Kagitani S, et al: Galantamine-induced amyloid- {β} clearance mediated via stimulation of microglial nicotinic acetylcholine receptors. J Biol Chem 285: 40180-40191, 2010
-
(2010)
J Biol Chem
, vol.285
, pp. 40180-40191
-
-
Takata, K.1
Kitamura, Y.2
Saeki, M.3
Terada, M.4
Kagitani, S.5
-
16
-
-
38449088916
-
Rivastigmine in the treatment of Alzheimer's disease: An update
-
Onor ML, Trevisiol M, Aguglia E: Rivastigmine in the treatment of Alzheimer's disease: an update. Clin Interv Aging 2: 17-32, 2007
-
(2007)
Clin Interv Aging
, vol.2
, pp. 17-32
-
-
Onor, M.L.1
Trevisiol, M.2
Aguglia, E.3
-
17
-
-
64149090366
-
Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: A review
-
Kurz A, Farlow M, Lefevre G: Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review. Int J Clin Pract 63: 799-805, 2009
-
(2009)
Int J Clin Pract
, vol.63
, pp. 799-805
-
-
Kurz, A.1
Farlow, M.2
Lefevre, G.3
-
18
-
-
13844251864
-
Empirical evidence of neuroprotection by dual cholinesterase inhibition in Alzheimer's disease
-
Venneri A, McGeown WJ, Shanks MF: Empirical evidence of neuroprotection by dual cholinesterase inhibition in Alzheimer's disease. Neuroreport 16: 107-110, 2005
-
(2005)
Neuroreport
, vol.16
, pp. 107-110
-
-
Venneri, A.1
McGeown, W.J.2
Shanks, M.F.3
-
19
-
-
75149131084
-
A novel effect of rivastigmine on pre-synaptic proteins and neuronal viability in a neurodegeneration model of fetal rat primary cortical cultures and its implication in Alzheimer's disease
-
Bailey JA, Lahiri DK: A novel effect of rivastigmine on pre-synaptic proteins and neuronal viability in a neurodegeneration model of fetal rat primary cortical cultures and its implication in Alzheimer's disease. J Neurochem 112: 843-853, 2010
-
(2010)
J Neurochem
, vol.112
, pp. 843-853
-
-
Bailey, J.A.1
Lahiri, D.K.2
-
20
-
-
53149137393
-
Suppression of neuroinflammation and immunomodulation by the acetylcholinesterase inhibitor rivastigmine
-
Nizri E, Irony-Tur-Sinai M, Faranesh N, Lavon I, Lavi E, et al: Suppression of neuroinflammation and immunomodulation by the acetylcholinesterase inhibitor rivastigmine. J Neuroimmunol 203: 12-22, 2008
-
(2008)
J Neuroimmunol
, vol.203
, pp. 12-22
-
-
Nizri, E.1
Irony-Tur-Sinai, M.2
Faranesh, N.3
Lavon, I.4
Lavi, E.5
-
21
-
-
68849109872
-
Progression from mild cognitive impairment to Alzheimer's disease: Effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment
-
Ferris S, Nordberg A, Soininen H, Darreh-Shori T, Lane R: Progression from mild cognitive impairment to Alzheimer's disease: effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment. Pharmacogenet Genomics 19: 635-646, 2009
-
(2009)
Pharmacogenet Genomics
, vol.19
, pp. 635-646
-
-
Ferris, S.1
Nordberg, A.2
Soininen, H.3
Darreh-Shori, T.4
Lane, R.5
-
22
-
-
0032892343
-
Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - A review of preclinical data
-
DOI 10.1016/S0028-3908(99)00019-2, PII S0028390899000192
-
Parsons CG, Danysz W, Quack G: Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - a review of preclinical data. Neuropharmacology 38: 735-767, 1999 (Pubitemid 29187336)
-
(1999)
Neuropharmacology
, vol.38
, Issue.6
, pp. 735-767
-
-
Parsons, C.G.1
Danysz, W.2
Quack, G.3
-
23
-
-
77950350271
-
Memantine: A review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias
-
Thomas SJ, Grossberg GT: Memantine: a review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias. Clin Interv Aging 4: 367-377, 2009
-
(2009)
Clin Interv Aging
, vol.4
, pp. 367-377
-
-
Thomas, S.J.1
Grossberg, G.T.2
-
25
-
-
56749091391
-
Longitudinal multimodal imaging in mild to moderate Alzheimer disease: A pilot study with memantine
-
Schmidt R, Ropele S, Pendl B, Ofner P, Enzinger C, et al: Longitudinal multimodal imaging in mild to moderate Alzheimer disease: a pilot study with memantine. J Neurol Neurosurg Psychiatry 79: 1312-1317, 2008
-
(2008)
J Neurol Neurosurg Psychiatry
, vol.79
, pp. 1312-1317
-
-
Schmidt, R.1
Ropele, S.2
Pendl, B.3
Ofner, P.4
Enzinger, C.5
-
26
-
-
34748915821
-
Reduction of phosphorylated tau during memantine treatment of Alzheimer's disease
-
DOI 10.1159/000107099
-
Degerman Gunnarsson M, Kilander L, Basun H, Lannfelt L: Reduction of phosphorylated tau during memantine treatment of Alzheimer's disease. Dement Geriatr Cogn Disord 24: 247-252, 2007 (Pubitemid 47482070)
-
(2007)
Dementia and Geriatric Cognitive Disorders
, vol.24
, Issue.4
, pp. 247-252
-
-
Degerman, G.M.1
Kilander, L.2
Basun, H.3
Lannfelt, L.4
-
27
-
-
57049085109
-
Memantine leads to behavioral improvement and amyloid reduction in Alzheimer's-disease-model transgenic mice shown as by micromagnetic resonance imaging
-
Scholtzova H, Wadghiri YZ, Douadi M, Sigurdsson EM, Li YS, et al: Memantine leads to behavioral improvement and amyloid reduction in Alzheimer's-disease-model transgenic mice shown as by micromagnetic resonance imaging. J Neurosci Res 86: 2784-2791, 2008
-
(2008)
J Neurosci Res
, vol.86
, pp. 2784-2791
-
-
Scholtzova, H.1
Wadghiri, Y.Z.2
Douadi, M.3
Sigurdsson, E.M.4
Li, Y.S.5
-
28
-
-
74149089703
-
Memantine treatment decreases levels of secreted Alzheimer's amyloid precursor protein (APP) and amyloid β (Aβ) peptide in the human neuroblastoma cells
-
Ray B, Banerjee PK, Greig NH, Lahiri DK: Memantine treatment decreases levels of secreted Alzheimer's amyloid precursor protein (APP) and amyloid β (Aβ) peptide in the human neuroblastoma cells. Neurosci Lett 470: 1-5, 2010
-
(2010)
Neurosci Lett
, vol.470
, pp. 1-5
-
-
Ray, B.1
Banerjee, P.K.2
Greig, N.H.3
Lahiri, D.K.4
-
29
-
-
42149142899
-
Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: A randomized, double-blind, placebo-controlled trial
-
DOI 10.2174/156720508783884576
-
Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT: Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res 5: 83-89, 2008 (Pubitemid 351536358)
-
(2008)
Current Alzheimer Research
, vol.5
, Issue.1
, pp. 83-89
-
-
Porsteinsson, A.P.1
Grossberg, G.T.2
Mintzer, J.3
Olin, J.T.4
-
30
-
-
66149095869
-
Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease
-
Lopez OL, Becker JT, Wahed AS, Saxton J, Sweet RA, et al: Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry 80: 600-607, 2009
-
(2009)
J Neurol Neurosurg Psychiatry
, vol.80
, pp. 600-607
-
-
Lopez, O.L.1
Becker, J.T.2
Wahed, A.S.3
Saxton, J.4
Sweet, R.A.5
-
31
-
-
21544467552
-
Cholinesterase inhibitors for patients with Alzheimer's disease: Systematic review of randomised clinical trials
-
Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H: Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ 331: 321-327, 2005
-
(2005)
BMJ
, vol.331
, pp. 321-327
-
-
Kaduszkiewicz, H.1
Zimmermann, T.2
Beck-Bornholdt, H.P.3
Van Den Bussche, H.4
-
32
-
-
33644658662
-
The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease
-
Loveman E, Green C, Kirby J, Takeda A, Picot J, et al: The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease. Health Technol Assess 10: iii-iv, ix-xi, 1-160, 2006
-
(2006)
Health Technol Assess
, vol.10
-
-
Loveman, E.1
Green, C.2
Kirby, J.3
Takeda, A.4
Picot, J.5
-
33
-
-
36849078870
-
Cholinesterase inhibitors in mild cognitive impairment: A systematic review of randomised trials
-
Raschetti R, Albanese E, Vanacore N, Maggini M: Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials. PLoS Med 4: e338, 2007
-
(2007)
PLoS Med
, vol.4
-
-
Raschetti, R.1
Albanese, E.2
Vanacore, N.3
Maggini, M.4
-
34
-
-
60749130048
-
Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer's disease: A meta-analysis
-
Campbell N, Ayub A, Boustani MA, Fox C, Farlow M, et al: Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer's disease: a meta-analysis. Clin Interv Aging 3: 719-728, 2008
-
(2008)
Clin Interv Aging
, vol.3
, pp. 719-728
-
-
Campbell, N.1
Ayub, A.2
Boustani, M.A.3
Fox, C.4
Farlow, M.5
-
35
-
-
47849119964
-
Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: A systematic review and meta-analysis
-
Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, et al: Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Clin Interv Aging 3: 211-225, 2008 (Pubitemid 352037861)
-
(2008)
Clinical Interventions in Aging
, vol.3
, Issue.2
, pp. 211-225
-
-
Hansen, R.A.1
Gartlehner, G.2
Webb, A.P.3
Morgan, L.C.4
Moore, C.G.5
Jonas, D.E.6
-
36
-
-
70350517148
-
Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine
-
Rodda J, Morgan S, Walker Z: Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine. Int Psychogeriatr 21: 813-824, 2009
-
(2009)
Int Psychogeriatr
, vol.21
, pp. 813-824
-
-
Rodda, J.1
Morgan, S.2
Walker, Z.3
|